Drug Research
Drug Discovery & Development

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
1-15 of 4654 results
Corvidia Therapeutics raises $60m funding to speed up clinical work
Corvidia Therapeutics has secured $60m in a Series B funding round to accelerate growth of its ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.
Drug Research > Drug Discovery & Development > News
Celgene expands bispecific antibody collaboration with Zymeworks
Zymeworks said that Celgene has exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutics using the former’s Azymetric platform.
Drug Research > Drug Discovery & Development > News
Scientists develop new method to make drugs smarter
Scientists from the University of Lincoln in the UK have created a new technique using nanotechnology which can make drugs more effective at reaching their target.
Drug Research > Drug Discovery & Development > News
Biogen to pay Ionis $1bn for neurological drugs development
By PBR Staff Writer
Biogen has entered into a new ten-year collaboration agreement with Ionis Pharmaceuticals for the development of antisense drug candidates to treat a range of neurological diseases.
Drug Research > Drug Discovery & Development > News
Tmunity raises another $35m to advance T Cell therapies
Tmunity Therapeutics, a biotherapeutics company focused on developing next-generation T cell immunotherapy, has raised new funding of $35m in a Series A investment from Kleiner Perkins and affiliates.
Drug Research > Drug Discovery & Development > News
Shire rejects $63bn takeover proposal from Takeda
By PBR Staff Writer
Ireland-based Shire has rejected a $63bn acquisition offer from Takeda Pharmaceutical, saying that it undervalues the company, its growth prospects and pipeline.
Drug Research > Drug Discovery & Development > News
BenevolentAI raises $115m to advance AI-enabled drug development activities
By PBR Staff Writer
BenevolentAI has secured $115m funding to advance drug development activities and extend its artificial intelligence (AI) platform capabilities.
Drug Research > Drug Discovery & Development > News
Sandoz, Pear to commercialize prescription digital therapeutics
Sandoz, a division of Novartis, and Pear Therapeutics have agreed to jointly commercialize and continue development of novel prescription digital therapeutics designed to treat disease and improve clinical outcomes for patients.
Drug Research > Drug Discovery & Development > News
Catabasis Pharmaceuticals to reduce workforce by about 42%
Catabasis Pharmaceuticals is restructuring its resources to focus on late-stage lead program, edasalonexent, for the treatment of Duchenne muscular dystrophy (DMD).
Drug Research > Drug Discovery & Development > News
Novartis to invest $100m into antimalarials research
Novartis said that it will invest more than $100m to advance research and development of new antimalarials over the next five years.
Drug Research > Drug Discovery & Development > News
Kalytera scraps pre-clinical programs in bone disease
Kalytera Therapeutics has announced the termination of its pre-clinical development programs in the treatment of bone disease to focus its resources on graft versus host disease (GVHD) and pain programs.
Drug Research > Drug Discovery & Development > News
Inovio secures $56m from CEPI to advance DNA vaccines against Lassa fever and MERS
Inovio Pharmaceuticals has secured funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop vaccine candidates against Lassa fever and Middle East Respiratory Syndrome (MERS).
Drug Research > Drug Discovery & Development > News
Orchard Therapeutics to buy GSK’s rare disease gene therapy portfolio
By EBR Staff Writer
Privately held clinical-stage biotechnology firm Orchard Therapeutics has agreed to acquire the rare disease gene therapy portfolio of GlaxoSmithKline (GSK).
Drug Research > Drug Discovery & Development > News
Mylan bags license to commercialize Fujifilm's Humira biosimilar in Europe
Mylan has acquired an exclusive license to commercialize a biosimilar to Humira (adalimumab), developed by Fujifilm Kyowa Kirin Biologics, in Europe.
Drug Research > Drug Discovery & Development > News
Alexion to acquire Wilson Therapeutics for $855m
By PBR Staff Writer
Alexion Pharmaceuticals has agreed to acquire Wilson Therapeutics, a Sweden-based company that develops therapies for rare copper-mediated disorders, for SEK7.1bn ($855m).
Drug Research > Drug Discovery & Development > News
1-15 of 4654 results